NCT05153941: DNS

Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures

Active, enrolled Last updated 3 October 2025

What this trial tests

trial in Alzheimer's Disease in 3,500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 January 2022

Primary endpoint
31 January 2029

31 January 2030

Quick facts

Lead sponsor	Altoida
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	3,500
Start date	31 January 2022
Primary completion	31 January 2029
Estimated completion	31 January 2030
Sites	1 location across Greece

Conditions studied

• Alzheimer's Disease — all drugs for Alzheimer's Disease →
• Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Altoida

Who can join

50 and older, any sex, with Alzheimer's Disease or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alzheimer's disease (AD) clinically characterized by the cognitive impairment and lowering of various functional abilities lead to staggering costs and suffering, which are particularly related to the social impacts of caring for increasingly disabled individuals. Some of these changes can be almost undetectable in the early stages of the disease, worsening over time often and at a varying rate of progression in different people. The traditional clinical scales or questionnaires such as ADCS (Alzheimer's Disease Cooperative Study) - ADL (Activities of Daily Living) for detecting such functional disabilities are typically blunt and rely on direct observation or caregiver recall. Digital technologies, particularly those based on the use of smart phones, wearable and/or home-based monitoring devices, here defined as 'Remote Measurement Technologies' (RMTs), provide an opportunity to change radically the way in which functional assessment is undertaken in AD, RMTs have potential to obtain better measurements of behavioral and biological parameters associated with individual Activities of Daily Living (ADL) when compared to the current subjective scales or questionnaires. Divergence from normative ADL profiles could objectively indicate the presence of incipient functional impairment at the very early stages of AD. Therefore, the main hypothesis of this study is that RMTs should allow the detection of impairments in functional components of ADLs that occur below the detection threshold of clinical scale or questionnaires.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.